Cargando…
Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study
Millions of people throughout the world suffer from the acquired condition of hyperpigmentation known as melasma. Melasma is characterized by symmetrically oriented hyperpigmented macules and patches. Many treatment options are available with variable degrees of efficacy and tolerability. The aim of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338558/ https://www.ncbi.nlm.nih.gov/pubmed/36856856 http://dx.doi.org/10.1007/s00403-023-02580-y |
_version_ | 1785071653896585216 |
---|---|
author | Abd Elraouf, Israa Gomaa Obaid, Zakaria Mahran Fouda, Ibrahim |
author_facet | Abd Elraouf, Israa Gomaa Obaid, Zakaria Mahran Fouda, Ibrahim |
author_sort | Abd Elraouf, Israa Gomaa |
collection | PubMed |
description | Millions of people throughout the world suffer from the acquired condition of hyperpigmentation known as melasma. Melasma is characterized by symmetrically oriented hyperpigmented macules and patches. Many treatment options are available with variable degrees of efficacy and tolerability. The aim of the work was to evaluate and compare the effectiveness and safety of intradermal tranexamic acid (TXA) versus intradermal platelet-rich plasma (PRP) in the treatment of various types of melasma. The current split-face prospective study included 40 cases with melasma. Tranexamic acid (TXA) was injected intradermally into the right side of the face by using a concentration of 4 mg/ml, while platelet-rich plasma (PRP) was injected intradermally into the left side. In both sides, a total of three sessions of treatment were provided, once every 4 weeks. Digital photographs were taken before each treatment session and 3 months after the last session. The modified melasma area severity index (mMASI) grading system and dermoscopy were used to assess the improvement in the condition. The disease severity and percentage of improvement were assessed by mMASI score before and after therapy across both sides of the face. along with determining the degree of satisfaction and side effects among the included cases. The mean mMASI score before therapy in the TXA side was 4.59 ± 2.87, while in the PRP side, the mean mMASI score before therapy was 4.72 ± 2.72 with no statistically significant difference between the two sides (p = 0.841). After 3 months of treatment, the mean mMASI score in the TXA-treated side was 2.49 ± 1.58 with a mean percentage of decrease of 45.67 ± 8.10%, while in the PRP side, the mean mMASI score after treatment was 2.17 ± 1.41 with a mean percentage of decrease of 53.66 ± 11.27%. There was a high statistically significant decrease in the mMASI score after treatment on both sides (p < 0.001); however, the percentage of score reduction in the PRP side compared to the TXA side was statistically higher. Intradermal injection with PRP revealed higher efficacy in the treatment of melasma as compared to TXA injection with no significant difference regarding the associated side effects. |
format | Online Article Text |
id | pubmed-10338558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-103385582023-07-14 Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study Abd Elraouf, Israa Gomaa Obaid, Zakaria Mahran Fouda, Ibrahim Arch Dermatol Res Study Protocol Millions of people throughout the world suffer from the acquired condition of hyperpigmentation known as melasma. Melasma is characterized by symmetrically oriented hyperpigmented macules and patches. Many treatment options are available with variable degrees of efficacy and tolerability. The aim of the work was to evaluate and compare the effectiveness and safety of intradermal tranexamic acid (TXA) versus intradermal platelet-rich plasma (PRP) in the treatment of various types of melasma. The current split-face prospective study included 40 cases with melasma. Tranexamic acid (TXA) was injected intradermally into the right side of the face by using a concentration of 4 mg/ml, while platelet-rich plasma (PRP) was injected intradermally into the left side. In both sides, a total of three sessions of treatment were provided, once every 4 weeks. Digital photographs were taken before each treatment session and 3 months after the last session. The modified melasma area severity index (mMASI) grading system and dermoscopy were used to assess the improvement in the condition. The disease severity and percentage of improvement were assessed by mMASI score before and after therapy across both sides of the face. along with determining the degree of satisfaction and side effects among the included cases. The mean mMASI score before therapy in the TXA side was 4.59 ± 2.87, while in the PRP side, the mean mMASI score before therapy was 4.72 ± 2.72 with no statistically significant difference between the two sides (p = 0.841). After 3 months of treatment, the mean mMASI score in the TXA-treated side was 2.49 ± 1.58 with a mean percentage of decrease of 45.67 ± 8.10%, while in the PRP side, the mean mMASI score after treatment was 2.17 ± 1.41 with a mean percentage of decrease of 53.66 ± 11.27%. There was a high statistically significant decrease in the mMASI score after treatment on both sides (p < 0.001); however, the percentage of score reduction in the PRP side compared to the TXA side was statistically higher. Intradermal injection with PRP revealed higher efficacy in the treatment of melasma as compared to TXA injection with no significant difference regarding the associated side effects. Springer Berlin Heidelberg 2023-03-01 2023 /pmc/articles/PMC10338558/ /pubmed/36856856 http://dx.doi.org/10.1007/s00403-023-02580-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Study Protocol Abd Elraouf, Israa Gomaa Obaid, Zakaria Mahran Fouda, Ibrahim Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study |
title | Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study |
title_full | Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study |
title_fullStr | Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study |
title_full_unstemmed | Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study |
title_short | Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study |
title_sort | intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338558/ https://www.ncbi.nlm.nih.gov/pubmed/36856856 http://dx.doi.org/10.1007/s00403-023-02580-y |
work_keys_str_mv | AT abdelraoufisraagomaa intradermalinjectionoftranexamicacidversusplateletrichplasmainthetreatmentofmelasmaasplitfacecomparativestudy AT obaidzakariamahran intradermalinjectionoftranexamicacidversusplateletrichplasmainthetreatmentofmelasmaasplitfacecomparativestudy AT foudaibrahim intradermalinjectionoftranexamicacidversusplateletrichplasmainthetreatmentofmelasmaasplitfacecomparativestudy |